Product logins

Find logins to all Clarivate products below.


Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay treatments for SLE. Unfortunately, many patients with SLE fail to respond to these therapies and/or experience significant adverse events. Clinicians may then prescribe other available agents, such as the biologics Benlysta (GlaxoSmithKline), Saphnelo (AstraZeneca), Rituxan (Roche; off-label), and Orencia (BMS; off-label) or the novel calcineurin inhibitor Lupkynis (Aurinia). This content gives manufacturers of current treatments and developers of novel SLE agents insight into the use of SLE drugs and market trends in the SLE space.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SLE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SLE patients?
  • How have Benlysta, Saphnelo, and Lupkynis been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of SLE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of SLE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: GlaxoSmithKline, AstraZeneca, Aurinia

Key drugs: Benlysta, Rituxan, Saphnelo, Lupkynis, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, tacrolimus, mycophenolate sodium, Orencia

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…